Sanofi has reported a net income of €683m, or €0.54 per share, for the fourth quarter (Q4) ended 31 December 2024, compared to a net loss of €555m, or €0.44 per share, for the same quarter in 2023.
The pharmaceutical company’s net income for Q4 2024 decreased compared to €2.81bn for the preceding quarter, the third quarter of 2024 (Q3 2024).
Sanofi reported net sales of €10.56bn for Q4 2024, a 9% rise compared to €9.68bn for the same quarter in 2023, and a 21% decline compared to €13.43bn for Q3 2024.
The French drugmaker reported an operating income of €1.18bn for Q4 2024, compared to €384m for the respective quarter in the previous year.
The company reported an income before tax of €880m for Q4 2024, compared to a loss before tax of €119m for the same period in 2023.
Sanofi CEO Paul Hudson said: “We achieved double-digit sales growth in 2024 while pursuing the transformation of the company.
“In 2024, we announced an intention to sell a controlling stake in Opella consumer health, which will make Sanofi a focused, science-driven biopharma company.
“We increased R&D investments and achieved significant progress with our pipeline in 2024, including positive phase 3 study results for new medicines such as rilzabrutinib in rare diseases and tolebrutinib in multiple sclerosis.”
Sanofi reported a net income of €5.74bn, or €4.59 per share, for the full year 2024, a 6% rise compared to €5.4bn, or €4.31 per share, for the full year 2023.
The company reported net sales of €41.08bn for the full year 2024, an 8.5% increase compared to €37.81bn for FY 2023.
Sanofi reported an operating income of €7.5bn for the full year 2024, a 7.5% rise compared to €6.7bn for the full year 2023.
The French drugmaker reported an income before tax of €6.7 for the full year 2024, an 11% increase compared to €6.2bn for the full year 2023.
Recently, Sanofi partnered with US-based biotech company Alloy Therapeutics to use the latter’s AntiClastic Antisense Platform to develop a central nervous system (CNS) target.
